Anticonvulsant effects of novel and repurposed drugs on docetaxel-induced neuropathy in C. elegans
Fig 6
Acute treatment with RVM 3 decreases the duration of shock-induced seizure-like behaviors that accompany chronic exposure to docetaxel.
(A) Acute treatment with RVM 3 significantly decreases time to recovery for worms treated with chronic 0.005 mM docetaxel. Different letters denote a statistically significant difference in the mean values between the groups where “a” stands for not statistically significantly different from M9 saline, and “b” stands for statistically significantly different from M9 saline (Student-Newman Keuls, P < 0.05). Data shown as mean ± s.e.m. (B) Acute treatment with RVM 3 does not decrease the percentage of non-recovered worms subjected to chronic 0.005 mM docetaxel exposure. 100 µM RVM3 vs. M9, X2 = 0.1079, p = 0.7425; C.E. 0.005 mM DTX vs. M9, X2 = 3.6308, p = 0.0567; C.E. 0.005mM DTX vs. 100 µM RVM3 + C.E. 0.005 mM DTX, X2 = 0.0021, p = 0.9634. *, p < 0.05, compared to M9. RVM-3, Resveramorph 3; C.E DTX, chronic exposure to 0.005 mM docetaxel.